RESUMEN
OBJECTIVE: To define an algorithm to improve diagnosis of neonatal hemochromatosis (NH) related to gestational alloimmune liver disease (GALD), which is diagnosed by immunohistochemistry demonstrating activated complement at hepatocytes (IDACH). STUDY DESIGN: We assessed 56 instances of fetal death or neonatal liver failure (NLF; 2006-2009), 29 (7 stillborns, 22 NLF) with NH, and 27 (5 stillborns, 22 NLF) without NH (non-NH). Immunohistochemistry was retrospectively performed in 21 cases. Cases were grouped as follows: (1) GALD as demonstrated by IDACH (n = 17); (2) indeterminate for GALD (n = 28); or (3) alternate diagnosis found (n = 11). We compared cases of immunohistochemically proven GALD with those with an alternate diagnosis. RESULTS: Of the 12 stillborns, 7 had NH because of GALD (NH-GALD), one was undeterminate, and 4 had alternate diagnoses (GALD excluded). Of the 22 newborns with NH, 6 had NH-GALD, one had mitochondrial respiratory chain disorder (MRCD), and 15 were indeterminate for GALD. Of 22 non-NH newborns, extrahepatic siderosis (EHS) was not assessed in 13 (3 GALD, 1 alternate diagnosis [MRCD] and 9 indeterminate GALD) and excluded in 9 (5 alternate diagnoses and 4 indeterminate GALD). The only clinical features found to be associated with GALD were intrafamilial recurrence, prematurity, and EHS. CONCLUSIONS: In unexplained fetal death or NLF, the diagnosis of subsets of NH requires tissue analysis (autopsy) to assess EHS. In patients with NH, if MRCD is ruled out, NH-GALD is likely. The rate of IDACH in the diagnosis of GALD in cases without NH requires further study.
Asunto(s)
Muerte Fetal/etiología , Hemocromatosis/diagnóstico , Hepatocitos/metabolismo , Fallo Hepático/etiología , Autopsia , Femenino , Feto , Francia , Hemocromatosis/complicaciones , Humanos , Inmunohistoquímica , Recién Nacido , Fallo Hepático/metabolismo , Masculino , Linaje , Embarazo , Estudios Retrospectivos , MortinatoRESUMEN
Childhood obliterative portal venopathy presents at any age and may be genetic in origin. We report 48 children with obliterative portal venopathy, based on strict histologic criteria, investigated between 1972 and 2011. Diagnosis requires histology and is suggested by ultrasonography findings. Portal hypertension is the main complication but is absent in some cases. Prognosis is relatively good, but the detection of cardiopulmonary complications is essential.
Asunto(s)
Hipertensión Portal/complicaciones , Hígado/patología , Vena Porta/patología , Enfermedades Vasculares/complicaciones , Adolescente , Niño , Preescolar , Femenino , Humanos , Hipertensión Portal/diagnóstico , Lactante , Recién Nacido , Masculino , Pronóstico , Enfermedades Vasculares/diagnósticoRESUMEN
OBJECTIVE: To assess the outcome of giant cell hepatitis combined with autoimmune hemolytic anemia in early childhood. STUDY DESIGN: We report on 16 children with this disease evaluated over a 28-year period. RESULTS: Children (nine boys; median age, 6 months) presented with jaundice, hepatomegaly, elevated aminotransferases, a positive Coombs test, and diffuse giant-cell transformation of hepatocytes on histology. Treatment with prednisone and azathioprine, plus, in three children, cyclosporine, resulted in complete remission in eight, partial remission in six, and failure in two. Relapses of hepatitis and/or anemia occurred in 11 and 10 children, respectively, requiring prolonged high levels of immunosuppression, and splenectomy or Rituximab, respectively. Treatment was stopped after a mean duration of 6 years, with no relapse, in seven children, with a median follow-up of 14 years. One child is alive 9 years after liver transplantation. Four children died of sepsis or multiple organ failure. CONCLUSIONS: Giant cell hepatitis combined with autoimmune hemolytic anemia requires rigorous treatment. Immunosuppressive therapy results in remission in most cases. A complete cure can be expected after several years of intensive treatment. Liver transplantation may be associated with prolonged survival.
Asunto(s)
Anemia Hemolítica Autoinmune/complicaciones , Anemia Hemolítica Autoinmune/terapia , Células Gigantes/patología , Hepatitis/complicaciones , Hepatitis/terapia , Hígado/patología , Anemia Hemolítica Autoinmune/mortalidad , Anticuerpos Monoclonales de Origen Murino/uso terapéutico , Azatioprina/uso terapéutico , Bilirrubina/sangre , Prueba de Coombs , Ciclosporina/uso terapéutico , Femenino , Estudios de Seguimiento , Glucocorticoides/uso terapéutico , Hepatitis/mortalidad , Hepatocitos/patología , Hepatomegalia/etiología , Humanos , Factores Inmunológicos/uso terapéutico , Inmunosupresores/uso terapéutico , Lactante , Ictericia/etiología , Trasplante de Hígado , Masculino , Insuficiencia Multiorgánica/mortalidad , Prednisona/uso terapéutico , Recurrencia , Inducción de Remisión , Rituximab , Sepsis/mortalidad , Esplenectomía , Esplenomegalia/etiología , Transaminasas/sangre , Resultado del Tratamiento , gammaglobulinas/análisisRESUMEN
We describe cholestasis as a result of bile duct abnormalities in 8 children with portal vein obstruction. In a clinical, biochemical and radiological investigation of 121 children with cavernous transformation of the portal vein seen between 1986 and 2000, 8 presented with jaundice, pruritus, and/or raised serum aminotransferases and/or gamma glutamyl transpeptidase (gamma GT) activities. Each displayed dilation and narrowing of intra- and/or extrahepatic bile ducts. Surgical decompression of the portal system (portal-systemic or Rex anastomosis) resulted in the regression of the signs of cholestasis in all children. We conclude that children with portal vein obstruction may exhibit clinically significant cholestasis as a result of external compression of the bile duct by the cavernoma.